INTERNATIONAL PATENT: TECLISON, INC. FILES APPLICATION FOR "MULTI-MODALITY PLATFORM IMMUNOTHERAPY AND TUMOR-SPECIFIC T CELLS"

GENEVA, Dec. 31 -- TECLISON, INC. (100 Overlook Center, 2nd Fl.Princeton, NJ 08540) filed a patent application (PCT/US2025/034448) for "MULTI-MODALITY PLATFORM IMMUNOTHERAPY AND TUMOR-SPECIFIC T CELLS" on Jun 20, 2025. With publication no. WO/2025/264968, the details related to the patent application was published on Dec 26, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): LEE, Ruey-min (28 Baltusrol WayShort Hills, NJ 07078)

Abstract: The present disclosure provides an autologous cell therapy for treating a cancer. Transarterial tirapazamine embolization (TATE) therapy induces tumor necrosi...